Estrella Immunopharma
ESLA
11 hedge funds and large institutions have $568K invested in Estrella Immunopharma in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 1 closing their positions.
67% more capital invested
Capital invested by funds: $341K → $568K (+$227K)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0.89% more ownership
Funds ownership: 0.81% → 1.7% (+0.89%)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$282K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$101K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.43K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.04K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$26.5K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$12.8K |
| 3 |
BlackRock
New York
|
-$512 |
| 4 |
JP Morgan Chase
New York
|
-$3 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $257K | +$282K | +255,894 | +1,180% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $92.9K | +$7.43K | +6,755 | +7% |
|
|
3
Citadel Advisors
Miami,
Florida
| $84.9K | +$101K | +91,599 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $38K | -$26.5K | -24,133 | -37% |
|
|
ASM
5
ATW SPAC Management
New York
| $37.1K | – | – | – |
|
|
6
BlackRock
New York
| $22.9K | -$512 | -465 | -2% |
|
7
State Street
Boston,
Massachusetts
| $20.7K | – | – | – |
|
|
MCP
8
Maso Capital Partners
Hong Kong
| $9.27K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $5.23K | +$2.04K | +1,858 | +49% |
|
|
10
Bank of America
Charlotte,
North Carolina
| $81 | +$4 | +4 | +5% |
|
|
11
JP Morgan Chase
New York
| $21 | -$3 | -3 | -12% |
|
|
TSS
12
Two Sigma Securities
New York
| – | -$12.8K | -10,640 | Closed |
|
ESLA Hedge Fund Activity: Q1 2025 in Review
11 of the 7,464 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q1 2025, worth a combined $568K — up 67% from $341K a quarter earlier.
Fund positioning in ESLA was balanced in Q1 2025: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $282K. The largest seller was UBS Group, cutting an estimated $26.5K.
- 11 institutional investors held Estrella Immunopharma (ESLA) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $568K of Estrella Immunopharma stock for Q1 2025, up 67% quarter-over-quarter.
- 1 fund opened new Estrella Immunopharma positions in Q1 2025 and 1 closed out, a net change of 0 holders.
- The largest Estrella Immunopharma buyer in Q1 2025 was Vanguard Group, an estimated $282K added.
- The largest Estrella Immunopharma seller in Q1 2025 was UBS Group, an estimated $26.5K sold.
Based on aggregated 13F filings for Q1 2025.